Taken together, the authors' results demonstrate that increased levels of miR-221 and -222 may modulate sensitivity of NSCLC cells to TRAIL with important implications in the design of new therapeutic agents. The gene discussed is TNFSF10; the disease is non-small cell lung carcinoma.